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Abstract
Background:  Bloodstream infections are frequent causes of human illness and cause major
morbidity and death. In order to best define the epidemiology of these infections and to track
changes in occurrence, adverse outcome, and resistance rates over time, population based
methodologies are optimal. However, few population-based surveillance systems exist worldwide,
and because of differences in methodology inter-regional comparisons are limited. In this report
we describe the rationale and propose first practical steps for developing an international
collaborative approach to the epidemiologic study and surveillance for bacteremia.
Findings: The founding collaborative participants represent six regions in four countries in three
continents with a combined annual surveillance population of more than 8 million residents.
Conclusion: Future studies from this collaborative should lead to a better understanding of the
epidemiology of bloodstream infections.
Introduction
Bloodstream infections are among the most important
causes of death in developed countries and cause signifi-
cant morbidity and healthcare cost [1-5]. Bloodstream
infections may arise in community-based patients, or may
complicate patients course admitted to hospital as noso-
comial infections. Population-based studies conducted in
Denmark (1981–1994), Finland (1995–2002), and the
United States (2003–2005) have reported overall inci-
dence rates ranging from 76 to 189 per 100,000/year with
the highest rates observed in the most recent years [2,4,5].
One study from Canada reported that community-onset
bloodstream had a similar acute burden of disease as each
of major trauma, stroke, and myocardial infarction [1].
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Population-based surveillance has been recognized as an
optimal means to define burden of disease, evaluate risk
factors for acquiring infections, and for monitoring tem-
poral trends in occurrence and resistance. Because all epi-
sodes of disease occurring in a defined population at risk
are included in these designs, selection bias is minimized
and calculation of incidence and mortality rates are facili-
tated [6]. Several regions worldwide have reported on
population-based bloodstream infection surveillance data
or systems including Australia [7,8], Canada [1,9-11],
Denmark [12-15], Iceland [16,17], Finland [4,18-20], and
the United States [2]. National programs with high cover-
age for selected blood culture pathogens are also operative
in a number of European countries [21-24]. However, to
date approaches between intercontinental regions have
not been coordinated.
A coordinated multi-national effort would have numer-
ous potential benefits. First, inter-regional (national, con-
tinental) differences in incidence, risk factors, outcomes,
and resistance rates may be directly compared. Second, a
surveillance region spanning several countries in different
continents that includes a large (millions per year) sur-
veillance population would allow the study of rare iso-
lates and facilitate the early detection of emerging
organisms. Finally, the recognition of the importance of
globalization of trade and international travel in the
spread of multi-resistant bacterial pathogens including
extended spectrum β-lactamase producing Escherichia coli
and Salmonella typhimurium DT104 has highlighted that
infectious diseases control is a global concern [25,26].
While initially this proposed collaborative will include a
few selected regions within developed countries, the ulti-
mate goal will be broad multi-national participation.
Methods and design
There are two requirements for centers to participate in
the collaborative: 1) the area of surveillance must be geo-
graphically and demographically (age and gender distri-
bution known or estimated) definable and 2) all (≥90%)
positive blood cultures occurring among residents of the
surveillance population must be identified. Infections
identified but occurring in non-residents, and duplicate
specimens from residents must be able to be excluded. For
common blood culture contaminants, two positive cul-
tures within a five day period will be required for inclu-
sion.
While these features define a minimum criteria set for
involvement, it is also preferable, but not mandatory for
detailed microbiology results including antimicrobial sus-
ceptibility testing of isolates to be available. In addition,
detailed clinical information including co-morbidity data,
treatments rendered, and hospitalization duration and
outcome will be sought where feasible. It is desirable that
cases be definable as to location of onset, either as noso-
comial [first occurred >48 h (or 2 days) after hospital
admission or within 48 hours (2 days) of hospital dis-
charge] or community onset [first identified in commu-
nity or within 48 hours (2 days) of hospital admission].
There are currently six centres in four countries in three
continents presently participating in the developing col-
laborative. These centres are summarized in Table 1 and
each is described in further detail the following sections.
Table 1: Characteristics of the proposed participating sites
Region Population in 2007 Estimated 
ascertainment
Source of laboratory 
surveillance
Clinical and outcome 
data
Start of independent 
routine surveillance
Calgary Health Region, 
Canada





380,000 ≥95% Two public and one 
private laboratories
Routinely available 1998







580,000 100% Regional microbiology 
laboratory
Routinely available 1981
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Calgary Health Region, Calgary, Alberta, Canada
The Calgary Health Region (CHR) provides virtually all
acute medical and surgical care to the residents of the cit-
ies of Calgary and Airdrie and a large surrounding area
(37,000 km2; population 1.24 million) in the Province of
Alberta, Canada through the publicly funded health sys-
tem. The region is geographically well defined and iso-
lated from other major centers. Acute inpatient care is
provided principally through four major hospitals that
have more than 2,000 beds representing 95% of the bed
capacity in the region. One regional laboratory system
(Calgary Laboratory Services) performs ≈99% of all blood
culture testing from both community and hospitals in the
CHR. Since 2000 routine ongoing population-based lab-
oratory surveillance for all blood isolates has been under-
taken. A database has been developed that includes
detailed clinical and outcome data on all admitted bacter-
emic patients.
Canberra Region, Australia
The Canberra Region (TCR; population 380,000) includes
the city of Canberra within the Australian Capital Terri-
tory and the satellite city of Queanbeyan and several small
surrounding rural towns within the state of New South
Wales. The region is geographically well-defined and iso-
lated, with the nearest city Goulburn (population 21,000)
and tertiary care hospitals (Sydney), 100 and 300 kilome-
tres away respectively. TCR is serviced by three public hos-
pitals (730 beds combined) and three private hospitals
(335 beds combined). Three of the four microbiology lab-
oratories in TCR are included in routine surveillance and
are estimated to capture more than 95% of all positive
blood cultures in TCR. The one non-participating labora-
tory is a private laboratory based in Sydney that only pro-
vides non-acute outpatient services and rarely has positive
blood cultures. Basic demographic data (age, gender) and
residency status based on residential postcodes are availa-
ble for all cases, and since 1998 further clinical and out-
come data has been routinely available for all positive
blood cultures involving emergency department assess-
ments or hospital admissions within the two major public
hospitals.
Sherbrooke, Quebec, Canada
Sherbrooke (population 152,000) is the capital of Estrie,
a predominantly rural region located in southeastern
Quebec, Canada [11]. Sherbrooke is served by a single
microbiology laboratory located in the Centre Hospitalier
Universitaire de Sherbrooke, a 686-bed academic, tertiary
care centre. The population of the Estrie region is geo-
graphically captive, since no other major hospitals are
located within an 80 km radius. Consequently, an ascer-
tainment rate approaching 100% is estimated for surveil-
lance of bacteremias occurring among regional residents.
A clinical data warehouse articulated around a computer-
ized patient data system has been functional since 1999.
Detailed demographic, clinical, microbiological, and hos-
pital outcome data is therefore available.
National Infectious Disease Register (NIDR), Helsinki, 
Finland
Finland has a population of 5.3 million residents. All
acute care is administered through the publicly funded
National Health Care System. All Finnish clinical microbi-
ology laboratories report all bacterial isolations from
blood to the National Infectious Disease Register (NIDR).
With each notification, the following information is trans-
mitted: date and type of specimen, date of birth, gender,
and place of treatment and since 2004 each individual's
National Identity Code by which the dates of deaths can
be obtained from the national Population Information
System. Detailed clinical data on all the hospitalizations
of patients are available from the National Hospital Dis-
charge Registry (HILMO). This registry contains compre-
hensive health care records from all hospitals and
municipal health centers, including outpatient surgery.
While these detailed clinical data from the HILMO are
available, they are not routinely maintained as linked data
to bacteremias within the NIDR database.
North Denmark Region, Denmark
The North Denmark Region is located in the northern-
most part of the Jutland peninsula (8,000 km2; popula-
tion 580,000). The main city is Aalborg (population
195,000). The region was established by an administra-
tive reform effective 1 January 2007 and the core area is
the former North Jutland County (6,000 square kilom-
eters, population 495,000). Comprehensive hospital care
is provided through 4 publicly funded hospitals at 11 dif-
ferent sites with a total of 1700 beds. Aalborg Hospital
serves the city of Aalborg and is the regions' referral and
teaching hospital; the other hospitals are community-
based and some facilities offer specialized care only. Bac-
teriological services for the entire region are provided
through the Department of Clinical Microbiology at Aal-
borg Hospital. Since 1981 all episodes of bacteremia have
been registered in the North Jutland Bacteremia Research
Database. Detailed clinical and outcome data are availa-
ble through linkage between relevant administrative and
health registries databases including the Danish Civil Reg-
istration System and the Hospital Discharge Registry of
North Jutland [27].
Vancouver Island Health Authority (VIHA), British 
Columbia, Canada
The VIHA includes all of Vancouver Island and an adja-
cent area of the mainland of British Columbia, Canada.
The region (total population 746,000) is comprised by
three local health areas including the south (364,000)
that includes the provincial capital city of Victoria, theBMC Research Notes 2009, 2:146 http://www.biomedcentral.com/1756-0500/2/146
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central (262,000), and the north (120,000) covering a
total area of more than 56,000 square kilometres. VIHA
provides a broad range of community and hospital based
medical and surgical services through the publicly funded
health system. Inpatient care is provided through 15 facil-
ities representing a total acute care capacity of 1,500 beds.
Blood culture testing for all hospitals and the majority of
outpatients in VIHA is administered by the regional
microbiology laboratory. One private laboratory performs
outpatient blood cultures but this represents an estimated
<1% of all positive blood cultures in the region. Although
not routinely available in the microbiology database, an
advanced information technology infrastructure exists
whereby detailed clinical and outcome data may be
obtained on all admissions to the 15 acute care centres in
VIHA.
Discussion
This multinational surveillance co-operative aims to
develop a better understanding of the epidemiology of
bloodstream infections in several developed countries in
three continents. Because of the collaborative power from
a large combined surveillance area, the study of rare iso-
lates and patient groups will be enabled. For example,
Fusobacterium necrophorum is an uncommon but impor-
tant cause of bacteremia and is the principal causative
agent of Lemierre syndrome. Much of what is known
about this organism is based on compilations of anecdo-
tal case reports, and a single population-based study of 24
cases (incidence approximately 1.5 per million/year)
from Denmark [28]. Based on an incidence rate of 1–2 per
million per year, our collaborative would potentially be
able to systematically identify 100–200 incident cases
since 2000 based on our combined surveillance popula-
tion of more than 8 million residents per year. Another
advantage of our collaborative is that because the surveil-
lance population will represent a broad range of geo-
graphical regions, with mixtures of urban and rural
residents with a range of socioeconomic and demographic
differences, studies investigating the determinants of dis-
ease will be facilitated. For example, non-typhoidal Salmo-
nella species infections are principally related to animal
and contaminated food exposures [29]. If we observed
differences in incidence among regions, then ecological
associations between urbanicity, agricultural practices,
and food sources may be further explored. A final major
advantage is in the assessment of preventive interventions
at the population level such as with vaccination. This has
been exemplified by the introduction of universal 7-
valent pneumococcal conjugate vaccine in populations
with a subsequent reduction in both the target childhood
populations as well as adults. While several countries have
independently identified such an effect [30], our collabo-
rative would allow such an evaluation but with the advan-
tage of concurrent control populations where
interventions are introduced at different time periods
among regions.
There are a number of potential challenges. While in
many cases centre-based surveillance is currently sup-
ported through routinely funded programs, in others
resources have not been allocated and at present no spe-
cific funds have been allocated. Principal expenses include
support for database management, data analysis, and for
investigator meetings either directly or through telecon-
ference. A second major consideration is with the sharing
of data among the collaborative. In part because of both
patient confidentiality and intellectual property reasons, a
central collaborative database is not proposed. Rather,
each centre will autonomously maintain their own data-
base utilizing the collaborative definitions and will gener-
ate standardized summary reports. Each centre will
require compliance with the specific regulations for scien-
tific and ethical approval and data protection. Finally, we
are aware of the limitation that the collaborative currently
only includes six regions, all in developed countries. The
collaborative openly welcomes new participants that are
capable of providing the specified bacteriological and
demographic information. Regions in South America,
Africa and Asia would particularly valuable additions.
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